Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Phase 2 Study to Evaluate Efficacy and Safety of AL002 in Participants With Early Alzheimer's Disease (INVOKE-2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04592874
Recruitment Status : Recruiting
First Posted : October 19, 2020
Last Update Posted : April 29, 2021
Sponsor:
Collaborator:
AbbVie
Information provided by (Responsible Party):
Alector Inc.

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : June 30, 2023
Estimated Study Completion Date : August 30, 2023